Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BMEA NASDAQ:KLRS NASDAQ:LSTA NASDAQ:RANI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMEABiomea Fusion$1.60+5.3%$1.53$0.87▼$3.08$109.89M-0.321.84 million shs1.84 million shsKLRSKalaris Therapeutics$5.06-4.5%$7.23$2.14▼$11.88$121.86M0.1593,215 shs106,150 shsLSTALisata Therapeutics$3.26-0.3%$4.39$1.81▼$5.07$29.78M0.8196,900 shs43,830 shsRANIRani Therapeutics$0.96+8.6%$1.05$0.39▼$3.87$109.33M0.74793,739 shs1.02 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMEABiomea Fusion+5.26%+10.34%+5.96%+40.35%-5.21%KLRSKalaris Therapeutics-4.53%-8.17%-19.30%-39.40%+505,999,900.00%LSTALisata Therapeutics-0.31%+1.24%-34.80%-29.13%+37.84%RANIRani Therapeutics+8.62%+9.91%+15.66%-12.72%-11.10%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMEABiomea Fusion$1.60+5.3%$1.53$0.87▼$3.08$109.89M-0.321.84 million shs1.84 million shsKLRSKalaris Therapeutics$5.06-4.5%$7.23$2.14▼$11.88$121.86M0.1593,215 shs106,150 shsLSTALisata Therapeutics$3.26-0.3%$4.39$1.81▼$5.07$29.78M0.8196,900 shs43,830 shsRANIRani Therapeutics$0.96+8.6%$1.05$0.39▼$3.87$109.33M0.74793,739 shs1.02 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMEABiomea Fusion+5.26%+10.34%+5.96%+40.35%-5.21%KLRSKalaris Therapeutics-4.53%-8.17%-19.30%-39.40%+505,999,900.00%LSTALisata Therapeutics-0.31%+1.24%-34.80%-29.13%+37.84%RANIRani Therapeutics+8.62%+9.91%+15.66%-12.72%-11.10%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMEABiomea Fusion 2.89Moderate Buy$8.29417.86% UpsideKLRSKalaris Therapeutics 2.71Moderate Buy$14.00176.68% UpsideLSTALisata Therapeutics 2.00Hold$15.00360.12% UpsideRANIRani Therapeutics 2.67Moderate Buy$7.80712.42% UpsideCurrent Analyst Ratings BreakdownLatest LSTA, RANI, KLRS, and BMEA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026BMEABiomea Fusion CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy ➝ Outperform5/5/2026BMEABiomea Fusion Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$9.004/28/2026BMEABiomea Fusion D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.004/21/2026LSTALisata Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026BMEABiomea Fusion Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/16/2026KLRSKalaris Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$14.004/14/2026RANIRani Therapeutics Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$9.004/8/2026BMEABiomea Fusion D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.004/1/2026RANIRani Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.00 ➝ $5.003/27/2026RANIRani Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026BMEABiomea Fusion CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$6.00 ➝ $7.00(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMEABiomea FusionN/AN/AN/AN/A$0.42 per shareN/AKLRSKalaris TherapeuticsN/AN/AN/AN/A$4.21 per shareN/ALSTALisata Therapeutics$170K174.62N/AN/A$1.66 per share1.96RANIRani Therapeutics$1.63M72.72N/AN/A$0.34 per share2.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMEABiomea Fusion-$61.80M-$1.31N/AN/AN/AN/A-305.60%-128.09%N/AKLRSKalaris Therapeutics-$43.44M-$4.21N/AN/AN/AN/A-73.11%-43.56%N/ALSTALisata Therapeutics-$16.59M-$1.91N/AN/AN/AN/A-85.50%-70.85%5/7/2026 (Estimated)RANIRani Therapeutics-$29.67M-$0.59N/AN/AN/AN/A-774.04%-106.02%5/13/2026 (Estimated)Latest LSTA, RANI, KLRS, and BMEA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026RANIRani Therapeutics-$0.06N/AN/AN/A$1.13 millionN/A3/26/2026Q4 2025RANIRani Therapeutics-$0.03-$0.07-$0.04-$0.07$5.00 million$1.46 million3/17/2026Q4 2025KLRSKalaris Therapeutics-$0.56-$0.44+$0.12-$0.44N/AN/A3/12/2026Q4 2025LSTALisata Therapeutics-$0.74-$0.33+$0.41-$0.33N/A$0.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBMEABiomea FusionN/AN/AN/AN/AN/AKLRSKalaris TherapeuticsN/AN/AN/AN/AN/ALSTALisata TherapeuticsN/AN/AN/AN/AN/ARANIRani TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMEABiomea FusionN/A5.235.23KLRSKalaris TherapeuticsN/A12.2312.23LSTALisata TherapeuticsN/A5.765.76RANIRani TherapeuticsN/A4.214.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMEABiomea Fusion96.72%KLRSKalaris Therapeutics66.05%LSTALisata Therapeutics8.94%RANIRani Therapeutics30.19%Insider OwnershipCompanyInsider OwnershipBMEABiomea Fusion18.42%KLRSKalaris Therapeutics68.10%LSTALisata Therapeutics9.60%RANIRani Therapeutics26.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMEABiomea Fusion5072.30 million58.98 millionOptionableKLRSKalaris Therapeutics11022.99 million7.33 millionN/ALSTALisata Therapeutics309.11 million8.23 millionNot OptionableRANIRani Therapeutics110123.69 million90.90 millionOptionableLSTA, RANI, KLRS, and BMEA HeadlinesRecent News About These CompaniesRani Therapeutics (RANI) Projected to Post Earnings on WednesdayMay 6 at 6:29 AM | marketbeat.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $7.80 Average PT from AnalystsMay 1, 2026 | americanbankingnews.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Rating of "Moderate Buy" from AnalystsApril 26, 2026 | marketbeat.comRani Therapeutics (NASDAQ:RANI) Earns Buy Rating from Analysts at Lake Street CapitalApril 14, 2026 | marketbeat.comRani Therapeutics Holdings (RANI) price target decreased by 12.50% to 7.14April 9, 2026 | msn.comRani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical StrategyApril 9, 2026 | globenewswire.comThe Oral Delivery Revolution: Rani Therapeutics' Strategic PositionApril 2, 2026 | aktiencheck.deARani Therapeutics Holdings (RANI) price target decreased by 13.51% to 8.16March 27, 2026 | msn.comRani Therapeutics Holdings, Inc. (RANI) Q4 2025 Earnings Call TranscriptMarch 26, 2026 | seekingalpha.comRani Therapeutics Powers Ahead with Record-Breaking Q4 Results, Fueling Pipeline Growth and Platform ExpansionMarch 26, 2026 | news.themarketisopen.comNRani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate UpdateMarch 26, 2026 | globenewswire.comRani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline PrioritizationMarch 25, 2026 | globenewswire.comWhat To Expect From Rani Therapeutics Holdings Inc (RANI) Q4 2025 EarningsMarch 25, 2026 | finance.yahoo.comMaxim Group Keeps Their Buy Rating on Rani Therapeutics Holdings (RANI)March 21, 2026 | theglobeandmail.comRani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial ResultsMarch 19, 2026 | globenewswire.comRani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical OfficerJanuary 28, 2026 | globenewswire.comRetail investors account for 65% of Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) ownership, while private equity firms account for 17%January 23, 2026 | finance.yahoo.comRani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGenJanuary 8, 2026 | globenewswire.comRani Therapeutics finalizes governance and capital structure changesJanuary 2, 2026 | tipranks.comWhy Rani Therapeutics Holdings, Inc.’s (RANI) Stock Is Down 8.02%December 5, 2025 | aaii.comAWhy Rani Therapeutics Holdings, Inc.’s (RANI) Stock Is Up 6.88%December 4, 2025 | aaii.comANew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAmazon Stock Up 30%: Is AMZN Still a Buy Before Earnings?By Sam Quirke | April 22, 2026Amazon: Could Globalstar Be the Missing Spark the Stock Needs?By Sam Quirke | April 9, 20263 Overlooked Nuclear Fuel Supply Chain WinnersBy Nathan Reiff | April 26, 2026U.S.-Iran Ceasefire: Short Interest Surges for This Defense ETFBy Jessica Mitacek | April 13, 2026Amazon Stock Surges 20%: Can the Rally Survive Earnings?By Sam Quirke | April 14, 2026LSTA, RANI, KLRS, and BMEA Company DescriptionsBiomea Fusion NASDAQ:BMEA$1.60 +0.08 (+5.26%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$1.64 +0.04 (+2.81%) As of 05:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.Kalaris Therapeutics NASDAQ:KLRS$5.06 -0.24 (-4.53%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$5.19 +0.13 (+2.55%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.Lisata Therapeutics NASDAQ:LSTA$3.26 -0.01 (-0.31%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$3.14 -0.12 (-3.65%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.Rani Therapeutics NASDAQ:RANI$0.96 +0.08 (+8.62%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$0.95 -0.01 (-0.74%) As of 04:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage DigitalOcean’s AI Surge: How Far Can This Rally Go? Apple Talks Just Changed Everything for Intel Consolidate or Die: Is Rivian The Ultimate Takeover Target? Years in the Making, AMD’s Upside Movement Has Just Begun Capital One’s Big Bet Faces Rising Credit Risk Western Digital: The Storage Behemoth Skyrocketing on AI Demand Old Money, New Tech: Western Union's Crypto Reboot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
